Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 8, Issue 7, Pages e2921
Publisher
Springer Nature
Online
2017-07-13
DOI
10.1038/cddis.2017.314
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adenosine A1 Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea
- (2016) T. Kaur et al. JOURNAL OF NEUROSCIENCE
- CD24 Expression May Play a Role as a Predictive Indicator and a Modulator of Cisplatin Treatment Response in Head and Neck Squamous Cellular Carcinoma
- (2016) Vishnu Modur et al. PLoS One
- Distinct Expression Patterns Of Causative Genes Responsible For Hereditary Progressive Hearing Loss In Non-Human Primate Cochlea
- (2016) Makoto Hosoya et al. Scientific Reports
- STAT3 the oncogene - still eluding therapy?
- (2015) Matthew S. Wake et al. FEBS Journal
- Noise-induced damage to ribbon synapses without permanent threshold shifts in neonatal mice
- (2015) L. Shi et al. NEUROSCIENCE
- Loss of STAT1 protects hair cells from ototoxicity through modulation of STAT3, c-Jun, Akt, and autophagy factors
- (2015) S Levano et al. Cell Death & Disease
- Adenosine A3 Receptor Suppresses Prostate Cancer Metastasis by Inhibiting NADPH Oxidase Activity
- (2015) Sarvesh Jajoo et al. NEOPLASIA
- Cisplatin exposure damages resident stem cells of the mammalian inner Ear
- (2014) Eric L. Slattery et al. DEVELOPMENTAL DYNAMICS
- Reversal of Cisplatin Resistance by Epigallocatechin Gallate Is Mediated by Downregulation of Axl and Tyro 3 Expression in Human Lung Cancer Cells
- (2014) Kyung-Chan Kim et al. KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
- Downstream Targets of Lmo4 Are Modulated by Cisplatin in the Inner Ear of Wistar Rats
- (2014) Samson Jamesdaniel PLoS One
- Cochlear Inner Hair Cell Ribbon Synapse is the Primary Target of Ototoxic Aminoglycoside Stimuli
- (2013) Ke Liu et al. MOLECULAR NEUROBIOLOGY
- Time Courses of Changes in Phospho- and Total- MAP Kinases in the Cochlea after Intense Noise Exposure
- (2013) Yukihide Maeda et al. PLoS One
- Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications
- (2011) Brahma N. Singh et al. BIOCHEMICAL PHARMACOLOGY
- Protocol for MInimizing the Risk of Metachronous Adenomas of the CoLorectum with Green Tea Extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population
- (2011) Julia C Stingl et al. BMC CANCER
- Subcellular Distribution and Relative Expression of Fibrocyte Markers in the CD/1 Mouse Cochlea Assessed by Semiquantitative Immunogold Electron Microscopy
- (2011) Shanthini Mahendrasingam et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation
- (2011) T Kaur et al. Cell Death & Disease
- NOX3 NADPH Oxidase Couples Transient Receptor Potential Vanilloid 1 to Signal Transducer and Activator of Transcription 1-Mediated Inflammation and Hearing Loss
- (2010) Debashree Mukherjea et al. ANTIOXIDANTS & REDOX SIGNALING
- Molecular Anatomy of the Hair Cell's Ribbon Synapse
- (2010) R. C. Uthaiah et al. JOURNAL OF NEUROSCIENCE
- Tea Polyphenols Decrease Serum Levels of Prostate-Specific Antigen, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor in Prostate Cancer Patients and Inhibit Production of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor In vitro
- (2009) J. McLarty et al. Cancer Prevention Research
- Cisplatin-Induced Hair Cell Death Requires STAT1 and Is Attenuated by Epigallocatechin Gallate
- (2009) N. C. Schmitt et al. JOURNAL OF NEUROSCIENCE
- Adding Insult to Injury: Cochlear Nerve Degeneration after "Temporary" Noise-Induced Hearing Loss
- (2009) S. G. Kujawa et al. JOURNAL OF NEUROSCIENCE
- Mitotic activity and specification of fibrocyte subtypes in the developing rat cochlear lateral wall
- (2009) H. Mutai et al. NEUROSCIENCE
- Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies
- (2009) Leonard P Rybak et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Green Tea Extracts for the Prevention of Metachronous Colorectal Adenomas: A Pilot Study
- (2008) M. Shimizu et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays
- (2008) Colette Charpin et al. INTERNATIONAL JOURNAL OF CANCER
- Damage-Induced Activation of ERK1/2 in Cochlear Supporting Cells Is a Hair Cell Death-Promoting Signal That Depends on Extracellular ATP and Calcium
- (2008) M. Lahne et al. JOURNAL OF NEUROSCIENCE
- Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?
- (2008) B. D. Lawenda et al. JNCI-Journal of the National Cancer Institute
- Cisplatin-Induced Ototoxicity
- (2008) Gerhard W. Hill et al. OTOLOGY & NEUROTOLOGY
- Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
- (2008) Gabriella Regis et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
- EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer
- (2007) Sharmila Shankar Frontiers in Bioscience-Landmark
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started